Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews · Epilepsy

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 50%Low 2 · 50%Moderate 0 · 0%High 0 · 0%

VGB vs CBZ monotherapy

Time to treatment withdrawal · people with epilepsy

VGB showed no clear difference in time to treatment withdrawal compared with CBZ monotherapy (low certainty).

1 finding from 1 review

Vigabatrin versus carbamazepine monotherapy for epilepsy 2015 · Cochrane Headline outcomes only
HR 0.75 [0.52, 1.1]
1 study · 446 participants
Low

VGB vs CBZ monotherapy

Time to achieve 6‐month remission after the first 6 weeks of dose stabilisation from randomisation · people with epilepsy

It is very uncertain whether VGB changes time to achieve 6‐month remission after the first 6 weeks of dose… compared with CBZ monotherapy (very low certainty).

1 finding from 1 review

Vigabatrin versus carbamazepine monotherapy for epilepsy 2015 · Cochrane Headline outcomes only
HR 1.18 [0.89, 1.55]
1 study · 404 participants
Very low

VGB vs CBZ monotherapy

Time to first seizure (post‐randomisation) All participants Range of · people with epilepsy

VGB may leads to higher time to first seizure after randomisation compared with CBZ monotherapy (low certainty).

1 finding from 1 review

Vigabatrin versus carbamazepine monotherapy for epilepsy 2015 · Cochrane Headline outcomes only
HR 1.57 [1.23, 2.02]
1 study · 404 participants
Low

VGB vs CBZ monotherapy

Adverse events Visual field defects · people with epilepsy

It is very uncertain whether VGB changes adverse events Visual field defects compared with CBZ monotherapy (very low certainty).

1 finding from 1 review

Vigabatrin versus carbamazepine monotherapy for epilepsy 2015 · Cochrane Headline outcomes only
RR 5.37 [0.27, 106.88]
1 study · 54 participants
Very low